Milestone Pharmaceuticals Inc. (MIST) 10-Year Financial Performance & Capital Metrics

MIST •

HealthcareBiotechnologyCommercial Specialty Pharma

AboutMilestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.Show more

Revenue $0 -100.0%
EBITDA -$42M +31.2%
Net Income -$42M +30.4%
EPS (Diluted) -0.67 +51.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -277.55% -93.3%
ROIC -64.83% +18.0%
Debt/Equity 4.17 +35.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗High debt to equity ratio of 4.2x
✗Weak Piotroski F-Score: 2/9
✗Shares diluted 44.8% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-35.65%

EPS CAGR

10Y-

5Y-

3Y-

TTM7.78%

ROCE

10Y Avg-52.98%

5Y Avg-58.06%

3Y Avg-72.53%

Latest-62.2%

Peer Comparison

Commercial Specialty Pharma

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ALKSAlkermes plc	4.98B	30.10	21.05	-5.25%	16.37%	13.28%	0.01%	0.04
ADMAADMA Biologics, Inc.	3.71B	15.57	19.22	65.15%	42.87%	48.57%	2.97%	0.24
UTHRUnited Therapeutics Corporation	21.99B	503.90	18.09	10.61%	41.94%	18.81%	4.73%
PCSAProcessa Pharmaceuticals, Inc.	114.71M	2.17	-0.56			-221.71%		0.04
UNCYUnicycive Therapeutics, Inc.	144.49M	6.93	-1.24	-100%		-89.15%		0.10
PTHSPelthos Therapeutics Inc.	85.29M	26.36	-1.95		-318.41%	-40.48%
MISTMilestone Pharmaceuticals Inc.	145.64M	1.71	-2.55	-100%		-282.97%		4.17
AMRNAmarin Corporation plc	5.74B	13.80	-3.45	-25.51%	-38.01%	-18.78%		0.02

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	15M	5M	1M	0
Revenue Growth %	-	-	-	-	-	-66.67%	-80%	-100%
Cost of Goods Sold+	8K	10K	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	-8K	-10K	0	0	15M	5M	1M	0
Gross Margin %	-	-	-	-	100%	100%	100%	-
Gross Profit Growth %	-	-25%	100%	-	-	-66.67%	-80%	-100%
Operating Expenses+	8.27M	23.82M	57.88M	50.71M	58.07M	64.64M	62.1M	42.1M
OpEx % of Revenue	-	-	-	-	387.15%	1292.84%	6209.8%	-
Selling, General & Admin	2.63M	6.97M	15.62M	15.9M	19.4M	24.81M	31.05M	27.75M
SG&A % of Revenue	-	-	-	-	129.35%	496.26%	3104.6%	-
Research & Development	5.64M	16.85M	42.38M	34.86M	38.67M	39.83M	31.05M	14.36M
R&D % of Revenue	-	-	-	-	257.81%	796.58%	3105.2%	-
Other Operating Expenses	0	0	-115K	-55K	0	0	0	0
Operating Income+	-8.27M	-23.82M	-57.88M	-50.71M	-43.07M	-59.64M	-61.1M	-42.1M
Operating Margin %	-	-	-	-	-287.15%	-1192.84%	-6109.8%	-
Operating Income Growth %	-	-188.12%	-142.97%	12.39%	15.06%	-38.47%	-2.44%	31.09%
EBITDA+	-8.26M	-23.81M	-57.84M	-50.61M	-42.98M	-59.55M	-61.01M	-42M
EBITDA Margin %	-	-	-	-	-286.53%	-1191.06%	-6100.6%	-
EBITDA Growth %	-	-188.28%	-142.92%	12.5%	15.08%	-38.56%	-2.44%	31.16%
D&A (Non-Cash Add-back)	8K	10K	38K	97K	93K	89K	92K	105K
EBIT	-8.27M	-23.37M	-57.88M	-50.71M	-43.07M	-58.39M	-57.13M	-37.94M
Net Interest Income+	0	0	0	0	220K	1.25M	1.41M	7.75M
Interest Income	186K	711K	2.6M	726K	220K	1.25M	3.97M	4.16M
Interest Expense	0	0	2.6M	726K	0	0	2.55M	-3.58M
Other Income/Expense	186K	711K	2.6M	726K	220K	1.25M	1.41M	583K
Pretax Income+	-8.08M	-23.11M	55.28M	-49.98M	-42.85M	-58.39M	-59.69M	-41.52M
Pretax Margin %	-	-	-	-	-285.69%	-1167.76%	-5968.5%	-
Income Tax+	4K	74K	56K	-17K	0	0	0	0
Effective Tax Rate %	100.05%	100.32%	-99.9%	99.97%	100%	100%	100%	100%
Net Income+	-8.09M	-23.18M	-55.23M	-49.97M	-42.85M	-58.39M	-59.69M	-41.52M
Net Margin %	-	-	-	-	-285.69%	-1167.76%	-5968.5%	-
Net Income Growth %	-	-186.73%	-138.21%	9.53%	14.24%	-36.25%	-2.22%	30.44%
Net Income (Continuing)	-8.09M	-23.18M	-55.23M	-49.97M	-42.85M	-58.39M	-59.69M	-41.52M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.34	-0.98	-3.50	-1.70	-1.02	-1.35	-1.39	-0.67
EPS Growth %	-	-188.24%	-257.14%	51.43%	40%	-32.35%	-2.96%	51.8%
EPS (Basic)	-0.34	-0.98	-3.50	-1.70	-1.02	-1.35	-1.39	-0.67
Diluted Shares Outstanding	23.65M	23.65M	15.78M	29.34M	41.83M	42.45M	42.96M	62.21M
Basic Shares Outstanding	23.65M	23.65M	15.78M	29.34M	41.83M	42.45M	42.96M	62.21M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	27.55M	88.05M	122.5M	148.69M	118.92M	71.8M	73.03M	73.93M
Cash & Short-Term Investments	26.91M	85.98M	119.82M	142.31M	114.14M	64.58M	66M	69.69M
Cash Only	10.88M	85.95M	119.82M	72.31M	114.14M	7.64M	13.76M	25.31M
Short-Term Investments	16.03M	29K	0	70M	0	56.95M	52.24M	44.38M
Accounts Receivable	543K	677K	0	0	483K	1.21M	3.85M	2.39M
Days Sales Outstanding	-	-	-	-	11.75	88.55	1.41K	-
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	0	836K	948K	0	0	0	0
Total Non-Current Assets+	35K	30K	929K	1.29M	926K	2.68M	2.19M	1.57M
Property, Plant & Equipment	35K	30K	929K	1.29M	926K	2.68M	2.19M	1.57M
Fixed Asset Turnover	-	-	-	-	16.20x	1.87x	0.46x	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	0	0
Total Assets+	27.59M	88.08M	123.43M	149.97M	119.85M	74.48M	75.23M	75.5M
Asset Turnover	-	-	-	-	0.13x	0.07x	0.01x	-
Asset Growth %	-	219.25%	40.13%	21.51%	-20.09%	-37.85%	1%	0.36%
Total Current Liabilities+	1.6M	4.53M	8.33M	6.16M	6.78M	6.14M	7.23M	8.13M
Accounts Payable	4K	2.6M	4.38M	4.64M	4.38M	2.26M	3.98M	1.93M
Days Payables Outstanding	182.5	95.01K	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	224K	495K	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	1.11M	56K	0	0	709K	808K	1.99M	0
Current Ratio	17.17x	19.42x	14.71x	24.14x	17.55x	11.70x	10.11x	9.10x
Quick Ratio	17.17x	19.42x	14.71x	24.14x	17.55x	11.70x	10.11x	9.10x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	59.1M	138.76M	184K	696K	474K	2M	51.23M	54.23M
Long-Term Debt	0	0	0	0	0	0	49.77M	53.35M
Capital Lease Obligations	0	0	184K	696K	474K	2M	1.46M	874K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	59.1M	138.76M	0	0	0	0	0	0
Total Liabilities	60.71M	143.29M	8.51M	6.86M	7.25M	8.13M	58.45M	62.35M
Total Debt+	0	0	514K	941K	698K	2.49M	51.77M	54.8M
Net Debt	-10.88M	-85.95M	-119.3M	-71.37M	-113.44M	-5.14M	38.02M	29.48M
Debt / Equity	-	-	0.00x	0.01x	0.01x	0.04x	3.09x	4.17x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-22.30x	-69.85x	-	-	-23.92x	-
Total Equity+	-33.12M	-55.21M	114.92M	143.12M	112.6M	66.35M	16.77M	13.15M
Equity Growth %	-	-66.7%	308.15%	24.54%	-21.32%	-41.08%	-74.72%	-21.61%
Book Value per Share	-1.40	-2.33	7.28	4.88	2.69	1.56	0.39	0.21
Total Shareholders' Equity	-33.12M	-55.21M	114.92M	143.12M	112.6M	66.35M	16.77M	13.15M
Common Stock	1.23M	2.04M	226.25M	251.68M	251.9M	273.9M	260.5M	288.05M
Retained Earnings	-35.09M	-58.27M	-113.5M	-163.47M	-206.32M	-266.34M	-326.03M	-367.55M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	-1.63M	-1.63M	-1.63M	46.37M	51.31M	34.35M	48.46M	53.08M
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-8.05M	-21.05M	-51.15M	-50.73M	-33.22M	-52.47M	-46.42M	-28.85M
Operating CF Margin %	-	-	-	-	-221.49%	-1049.38%	-4642.4%	-
Operating CF Growth %	-	-161.38%	-143.05%	0.82%	34.51%	-57.93%	11.52%	37.86%
Net Income	-8.09M	-23.18M	-55.23M	-49.97M	-42.85M	-58.39M	-59.69M	-41.52M
Depreciation & Amortization	8K	10K	38K	97K	93K	89K	92K	105K
Stock-Based Compensation	190K	633K	1.19M	4.95M	7.28M	9.05M	9.53M	5.78M
Deferred Taxes	0	0	-1.63M	0	0	0	0	0
Other Non-Cash Items	59K	787K	1.63M	0	0	44K	2.39M	3.13M
Working Capital Changes	-164K	1.5M	2.85M	-5.81M	2.26M	-3.26M	1.24M	3.66M
Change in Receivables	147K	-134K	-169K	-112K	465K	-730K	-2.64M	1.46M
Change in Inventory	0	0	169K	0	0	0	0	0
Change in Payables	-222K	2.88M	3.52M	-2.08M	0	0	0	0
Cash from Investing+	-16.02M	16M	-384K	-70M	70M	-57.12M	4.76M	8.28M
Capital Expenditures	-36K	-5K	-413K	0	0	-272K	-112K	-33K
CapEx % of Revenue	-	-	-	-	-	5.44%	11.2%	-
Acquisitions	0	0	35.41M	0	0	0	0	0
Investments	-	-	-	-	-	-	-	-
Other Investing	-15.99M	16M	-35.41M	0	0	0	0	0
Cash from Financing+	30.72M	80.11M	85.41M	73.22M	5.05M	3.09M	47.79M	32.12M
Debt Issued (Net)	0	0	0	0	0	0	50M	0
Equity Issued (Net)	1000K	1000K	1000K	1000K	0	1000K	0	1000K
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0
Other Financing	-278K	461K	44K	48.31M	5.05M	458K	-2.21M	4.86M
Net Change in Cash	6.65M	75.07M	33.87M	-47.51M	41.83M	-106.5M	6.12M	11.55M
Free Cash Flow+	-8.09M	-21.05M	-51.56M	-50.73M	-33.22M	-52.74M	-46.54M	-28.88M
FCF Margin %	-	-	-	-	-221.49%	-1054.82%	-4653.6%	-
FCF Growth %	-	-160.27%	-144.95%	1.62%	34.51%	-58.74%	11.77%	37.94%
FCF per Share	-0.34	-0.89	-3.27	-1.73	-0.79	-1.24	-1.08	-0.46
FCF Conversion (FCF/Net Income)	1.00x	0.91x	0.93x	1.02x	0.78x	0.90x	0.78x	0.69x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-185%	-38.73%	-33.52%	-65.26%	-143.61%	-277.55%
Return on Invested Capital (ROIC)	-	-	-	-112.92%	-91.12%	-148.22%	-79.01%	-64.83%
Gross Margin	-	-	-	-	100%	100%	100%	-
Net Margin	-	-	-	-	-285.69%	-1167.76%	-5968.5%	-
Debt / Equity	-	-	0.00x	0.01x	0.01x	0.04x	3.09x	4.17x
Interest Coverage	-	-	-22.30x	-69.85x	-	-	-23.92x	-
FCF Conversion	1.00x	0.91x	0.93x	1.02x	0.78x	0.90x	0.78x	0.69x
Revenue Growth	-	-	-	-	-	-66.67%	-80%	-100%

US Stock Screener

...

Milestone Pharmaceuticals Inc. (MIST) 10-Year Financial Performance & Capital Metrics

MIST •

HealthcareBiotechnologyCommercial Specialty Pharma

Revenue $0 -100.0%
EBITDA -$42M +31.2%
Net Income -$42M +30.4%
EPS (Diluted) -0.67 +51.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -277.55% -93.3%
ROIC -64.83% +18.0%
Debt/Equity 4.17 +35.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗High debt to equity ratio of 4.2x
✗Weak Piotroski F-Score: 2/9
✗Shares diluted 44.8% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-35.65%

EPS CAGR

10Y-

5Y-

3Y-

TTM7.78%

ROCE

10Y Avg-52.98%

5Y Avg-58.06%

3Y Avg-72.53%

Latest-62.2%

Peer Comparison

Commercial Specialty Pharma

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ALKSAlkermes plc	4.98B	30.10	21.05	-5.25%	16.37%	13.28%	0.01%	0.04
ADMAADMA Biologics, Inc.	3.71B	15.57	19.22	65.15%	42.87%	48.57%	2.97%	0.24
UTHRUnited Therapeutics Corporation	21.99B	503.90	18.09	10.61%	41.94%	18.81%	4.73%
PCSAProcessa Pharmaceuticals, Inc.	114.71M	2.17	-0.56			-221.71%		0.04
UNCYUnicycive Therapeutics, Inc.	144.49M	6.93	-1.24	-100%		-89.15%		0.10
PTHSPelthos Therapeutics Inc.	85.29M	26.36	-1.95		-318.41%	-40.48%
MISTMilestone Pharmaceuticals Inc.	145.64M	1.71	-2.55	-100%		-282.97%		4.17
AMRNAmarin Corporation plc	5.74B	13.80	-3.45	-25.51%	-38.01%	-18.78%		0.02

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	15M	5M	1M	0
Revenue Growth %	-	-	-	-	-	-66.67%	-80%	-100%
Cost of Goods Sold+	8K	10K	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	-8K	-10K	0	0	15M	5M	1M	0
Gross Margin %	-	-	-	-	100%	100%	100%	-
Gross Profit Growth %	-	-25%	100%	-	-	-66.67%	-80%	-100%
Operating Expenses+	8.27M	23.82M	57.88M	50.71M	58.07M	64.64M	62.1M	42.1M
OpEx % of Revenue	-	-	-	-	387.15%	1292.84%	6209.8%	-
Selling, General & Admin	2.63M	6.97M	15.62M	15.9M	19.4M	24.81M	31.05M	27.75M
SG&A % of Revenue	-	-	-	-	129.35%	496.26%	3104.6%	-
Research & Development	5.64M	16.85M	42.38M	34.86M	38.67M	39.83M	31.05M	14.36M
R&D % of Revenue	-	-	-	-	257.81%	796.58%	3105.2%	-
Other Operating Expenses	0	0	-115K	-55K	0	0	0	0
Operating Income+	-8.27M	-23.82M	-57.88M	-50.71M	-43.07M	-59.64M	-61.1M	-42.1M
Operating Margin %	-	-	-	-	-287.15%	-1192.84%	-6109.8%	-
Operating Income Growth %	-	-188.12%	-142.97%	12.39%	15.06%	-38.47%	-2.44%	31.09%
EBITDA+	-8.26M	-23.81M	-57.84M	-50.61M	-42.98M	-59.55M	-61.01M	-42M
EBITDA Margin %	-	-	-	-	-286.53%	-1191.06%	-6100.6%	-
EBITDA Growth %	-	-188.28%	-142.92%	12.5%	15.08%	-38.56%	-2.44%	31.16%
D&A (Non-Cash Add-back)	8K	10K	38K	97K	93K	89K	92K	105K
EBIT	-8.27M	-23.37M	-57.88M	-50.71M	-43.07M	-58.39M	-57.13M	-37.94M
Net Interest Income+	0	0	0	0	220K	1.25M	1.41M	7.75M
Interest Income	186K	711K	2.6M	726K	220K	1.25M	3.97M	4.16M
Interest Expense	0	0	2.6M	726K	0	0	2.55M	-3.58M
Other Income/Expense	186K	711K	2.6M	726K	220K	1.25M	1.41M	583K
Pretax Income+	-8.08M	-23.11M	55.28M	-49.98M	-42.85M	-58.39M	-59.69M	-41.52M
Pretax Margin %	-	-	-	-	-285.69%	-1167.76%	-5968.5%	-
Income Tax+	4K	74K	56K	-17K	0	0	0	0
Effective Tax Rate %	100.05%	100.32%	-99.9%	99.97%	100%	100%	100%	100%
Net Income+	-8.09M	-23.18M	-55.23M	-49.97M	-42.85M	-58.39M	-59.69M	-41.52M
Net Margin %	-	-	-	-	-285.69%	-1167.76%	-5968.5%	-
Net Income Growth %	-	-186.73%	-138.21%	9.53%	14.24%	-36.25%	-2.22%	30.44%
Net Income (Continuing)	-8.09M	-23.18M	-55.23M	-49.97M	-42.85M	-58.39M	-59.69M	-41.52M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.34	-0.98	-3.50	-1.70	-1.02	-1.35	-1.39	-0.67
EPS Growth %	-	-188.24%	-257.14%	51.43%	40%	-32.35%	-2.96%	51.8%
EPS (Basic)	-0.34	-0.98	-3.50	-1.70	-1.02	-1.35	-1.39	-0.67
Diluted Shares Outstanding	23.65M	23.65M	15.78M	29.34M	41.83M	42.45M	42.96M	62.21M
Basic Shares Outstanding	23.65M	23.65M	15.78M	29.34M	41.83M	42.45M	42.96M	62.21M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	27.55M	88.05M	122.5M	148.69M	118.92M	71.8M	73.03M	73.93M
Cash & Short-Term Investments	26.91M	85.98M	119.82M	142.31M	114.14M	64.58M	66M	69.69M
Cash Only	10.88M	85.95M	119.82M	72.31M	114.14M	7.64M	13.76M	25.31M
Short-Term Investments	16.03M	29K	0	70M	0	56.95M	52.24M	44.38M
Accounts Receivable	543K	677K	0	0	483K	1.21M	3.85M	2.39M
Days Sales Outstanding	-	-	-	-	11.75	88.55	1.41K	-
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	0	836K	948K	0	0	0	0
Total Non-Current Assets+	35K	30K	929K	1.29M	926K	2.68M	2.19M	1.57M
Property, Plant & Equipment	35K	30K	929K	1.29M	926K	2.68M	2.19M	1.57M
Fixed Asset Turnover	-	-	-	-	16.20x	1.87x	0.46x	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	0	0
Total Assets+	27.59M	88.08M	123.43M	149.97M	119.85M	74.48M	75.23M	75.5M
Asset Turnover	-	-	-	-	0.13x	0.07x	0.01x	-
Asset Growth %	-	219.25%	40.13%	21.51%	-20.09%	-37.85%	1%	0.36%
Total Current Liabilities+	1.6M	4.53M	8.33M	6.16M	6.78M	6.14M	7.23M	8.13M
Accounts Payable	4K	2.6M	4.38M	4.64M	4.38M	2.26M	3.98M	1.93M
Days Payables Outstanding	182.5	95.01K	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	224K	495K	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	1.11M	56K	0	0	709K	808K	1.99M	0
Current Ratio	17.17x	19.42x	14.71x	24.14x	17.55x	11.70x	10.11x	9.10x
Quick Ratio	17.17x	19.42x	14.71x	24.14x	17.55x	11.70x	10.11x	9.10x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	59.1M	138.76M	184K	696K	474K	2M	51.23M	54.23M
Long-Term Debt	0	0	0	0	0	0	49.77M	53.35M
Capital Lease Obligations	0	0	184K	696K	474K	2M	1.46M	874K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	59.1M	138.76M	0	0	0	0	0	0
Total Liabilities	60.71M	143.29M	8.51M	6.86M	7.25M	8.13M	58.45M	62.35M
Total Debt+	0	0	514K	941K	698K	2.49M	51.77M	54.8M
Net Debt	-10.88M	-85.95M	-119.3M	-71.37M	-113.44M	-5.14M	38.02M	29.48M
Debt / Equity	-	-	0.00x	0.01x	0.01x	0.04x	3.09x	4.17x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-22.30x	-69.85x	-	-	-23.92x	-
Total Equity+	-33.12M	-55.21M	114.92M	143.12M	112.6M	66.35M	16.77M	13.15M
Equity Growth %	-	-66.7%	308.15%	24.54%	-21.32%	-41.08%	-74.72%	-21.61%
Book Value per Share	-1.40	-2.33	7.28	4.88	2.69	1.56	0.39	0.21
Total Shareholders' Equity	-33.12M	-55.21M	114.92M	143.12M	112.6M	66.35M	16.77M	13.15M
Common Stock	1.23M	2.04M	226.25M	251.68M	251.9M	273.9M	260.5M	288.05M
Retained Earnings	-35.09M	-58.27M	-113.5M	-163.47M	-206.32M	-266.34M	-326.03M	-367.55M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	-1.63M	-1.63M	-1.63M	46.37M	51.31M	34.35M	48.46M	53.08M
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-8.05M	-21.05M	-51.15M	-50.73M	-33.22M	-52.47M	-46.42M	-28.85M
Operating CF Margin %	-	-	-	-	-221.49%	-1049.38%	-4642.4%	-
Operating CF Growth %	-	-161.38%	-143.05%	0.82%	34.51%	-57.93%	11.52%	37.86%
Net Income	-8.09M	-23.18M	-55.23M	-49.97M	-42.85M	-58.39M	-59.69M	-41.52M
Depreciation & Amortization	8K	10K	38K	97K	93K	89K	92K	105K
Stock-Based Compensation	190K	633K	1.19M	4.95M	7.28M	9.05M	9.53M	5.78M
Deferred Taxes	0	0	-1.63M	0	0	0	0	0
Other Non-Cash Items	59K	787K	1.63M	0	0	44K	2.39M	3.13M
Working Capital Changes	-164K	1.5M	2.85M	-5.81M	2.26M	-3.26M	1.24M	3.66M
Change in Receivables	147K	-134K	-169K	-112K	465K	-730K	-2.64M	1.46M
Change in Inventory	0	0	169K	0	0	0	0	0
Change in Payables	-222K	2.88M	3.52M	-2.08M	0	0	0	0
Cash from Investing+	-16.02M	16M	-384K	-70M	70M	-57.12M	4.76M	8.28M
Capital Expenditures	-36K	-5K	-413K	0	0	-272K	-112K	-33K
CapEx % of Revenue	-	-	-	-	-	5.44%	11.2%	-
Acquisitions	0	0	35.41M	0	0	0	0	0
Investments	-	-	-	-	-	-	-	-
Other Investing	-15.99M	16M	-35.41M	0	0	0	0	0
Cash from Financing+	30.72M	80.11M	85.41M	73.22M	5.05M	3.09M	47.79M	32.12M
Debt Issued (Net)	0	0	0	0	0	0	50M	0
Equity Issued (Net)	1000K	1000K	1000K	1000K	0	1000K	0	1000K
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0
Other Financing	-278K	461K	44K	48.31M	5.05M	458K	-2.21M	4.86M
Net Change in Cash	6.65M	75.07M	33.87M	-47.51M	41.83M	-106.5M	6.12M	11.55M
Free Cash Flow+	-8.09M	-21.05M	-51.56M	-50.73M	-33.22M	-52.74M	-46.54M	-28.88M
FCF Margin %	-	-	-	-	-221.49%	-1054.82%	-4653.6%	-
FCF Growth %	-	-160.27%	-144.95%	1.62%	34.51%	-58.74%	11.77%	37.94%
FCF per Share	-0.34	-0.89	-3.27	-1.73	-0.79	-1.24	-1.08	-0.46
FCF Conversion (FCF/Net Income)	1.00x	0.91x	0.93x	1.02x	0.78x	0.90x	0.78x	0.69x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-185%	-38.73%	-33.52%	-65.26%	-143.61%	-277.55%
Return on Invested Capital (ROIC)	-	-	-	-112.92%	-91.12%	-148.22%	-79.01%	-64.83%
Gross Margin	-	-	-	-	100%	100%	100%	-
Net Margin	-	-	-	-	-285.69%	-1167.76%	-5968.5%	-
Debt / Equity	-	-	0.00x	0.01x	0.01x	0.04x	3.09x	4.17x
Interest Coverage	-	-	-22.30x	-69.85x	-	-	-23.92x	-
FCF Conversion	1.00x	0.91x	0.93x	1.02x	0.78x	0.90x	0.78x	0.69x
Revenue Growth	-	-	-	-	-	-66.67%	-80%	-100%

Milestone Pharmaceuticals Inc. (MIST) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare MIST vs Peers

vs UTHR

vs ZLAB

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Milestone Pharmaceuticals Inc. (MIST) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare MIST vs Peers

vs UTHR

vs ZLAB

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios